Profound Medical Corp (PRN) - Total Assets
Based on the latest financial reports, Profound Medical Corp (PRN) holds total assets worth CA$193.10 Million CAD (≈ $139.69 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Profound Medical Corp's book value for net asset value and shareholders' equity analysis.
Profound Medical Corp - Total Assets Trend (2014–2025)
This chart illustrates how Profound Medical Corp's total assets have evolved over time, based on quarterly financial data.
Profound Medical Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Profound Medical Corp's total assets of CA$193.10 Million consist of 54.0% current assets and 46.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 42.4% |
| Accounts Receivable | CA$9.87 Million | 5.1% |
| Inventory | CA$11.29 Million | 5.9% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$189.16K | 0.1% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Profound Medical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PRN market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Profound Medical Corp's current assets represent 54.0% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 42.4% of total assets in 2025, down from 100.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 5.9% of total assets.
Profound Medical Corp Competitors by Total Assets
Key competitors of Profound Medical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Profound Medical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.52 | 10.52 | 23.39 |
| Quick Ratio | 11.17 | 9.64 | 21.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$95.97 Million | CA$62.50 Million | CA$89.04 Million |
Profound Medical Corp - Advanced Valuation Insights
This section examines the relationship between Profound Medical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.31 |
| Latest Market Cap to Assets Ratio | 1.28 |
| Asset Growth Rate (YoY) | 174.9% |
| Total Assets | CA$193.10 Million |
| Market Capitalization | $246.52 Million USD |
Valuation Analysis
Above Book Valuation: The market values Profound Medical Corp's assets above their book value (1.28x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Profound Medical Corp's assets grew by 174.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Profound Medical Corp (2014–2025)
The table below shows the annual total assets of Profound Medical Corp from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$193.10 Million ≈ $139.69 Million |
+174.94% |
| 2024-12-31 | CA$70.23 Million ≈ $50.81 Million |
+59.95% |
| 2023-12-31 | CA$43.91 Million ≈ $31.76 Million |
-31.84% |
| 2022-12-31 | CA$64.42 Million ≈ $46.60 Million |
-25.76% |
| 2021-12-31 | CA$86.78 Million ≈ $62.77 Million |
-17.04% |
| 2020-12-31 | CA$104.60 Million ≈ $75.67 Million |
+249.97% |
| 2019-12-31 | CA$29.89 Million ≈ $21.62 Million |
-12.55% |
| 2018-12-31 | CA$34.18 Million ≈ $24.72 Million |
+54.15% |
| 2017-12-31 | CA$22.17 Million ≈ $16.04 Million |
+25.77% |
| 2016-12-31 | CA$17.63 Million ≈ $12.75 Million |
+15.44% |
| 2015-12-31 | CA$15.27 Million ≈ $11.05 Million |
+938.08% |
| 2014-12-31 | CA$1.47 Million ≈ $1.06 Million |
-- |
About Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more